KNSA
Kiniksa Pharmaceuticals
PEG ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: KNSA
- PEG Ratio
As of Sep 23, 2026, KNSA's PE to growth ratio of 0.04 reflects its valuation relative to its growth rate. This result reflects a P/E ratio of 71.1 measured against EPS growth of 1683.3%. When compared to the trailing 4-quarter average of 0.13, KNSA's PEG ratio reflects a 70% decrease.
KNSA PEG ratio history
Kiniksa Pharmaceuticals's four years historical PEG ratio has a mean of 0.43. Compared to historical data, KNSA's 0.04 PEG ratio represents a drop of 91%. KNSA hit its maximum PEG ratio of 3.29 during the Jun 2025 quarter over the last four years. The Jun 2023 quarter marked the lowest reading at 0.01, indicating the most favorable growth-adjusted valuation.
Kiniksa Pharmaceuticals PEG ratio by year
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| 2025 | 0.22 | 51.56 | 233.3% |
| 2024 | N/A | N/A | -400% |
| 2023 | N/A | 87.7 | -92.4% |
| 2022 | 0.03 | 5.67 | 214.8% |
| 2021 | N/A | N/A | 11.9% |
| 2020 | N/A | N/A | 12.7% |
| 2019 | N/A | N/A | 14.3% |
| 2018 | N/A | N/A | 90.3% |
| 2017 | N/A | N/A | 60.9% |
| 2016 | N/A | N/A | N/A |
Kiniksa Pharmaceuticals PEG ratio by quarter (TTM)
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| Jun 2026 | 0.04 | 59.77 | 1,683.3% |
| Mar 2026 | 0.1 | 49.13 | 508.3% |
| Dec 2025 | 0.22 | 51.56 | 233.3% |
| Sep 2025 | 0.17 | 79.24 | 476.9% |
| Jun 2025 | 3.29 | 461.17 | 140% |
| Mar 2025 | N/A | N/A | -300% |
| Dec 2024 | N/A | N/A | -400% |
| Sep 2024 | N/A | N/A | -18.2% |
| Jun 2024 | N/A | N/A | -104.5% |
| Mar 2024 | N/A | 164.42 | -95.7% |
| Dec 2023 | N/A | 87.7 | -92.4% |
| Sep 2023 | N/A | N/A | -105.3% |
| Jun 2023 | 0.01 | 4.24 | 306.2% |
| Mar 2023 | 0.02 | 3.82 | 246.1% |
| Dec 2022 | 0.03 | 5.67 | 214.8% |
KNSA average PEG ratio chart
When comparing to historical data, KNSA's PEG ratio is lower than the 3 and 5-year averages.
PEG comparison
With a PEG of 0.04, KNSA stands lower than the Healthcare sector and the industry average. Looking at the Healthcare sector average of 0.53, Kiniksa Pharmaceuticals's PEG is 92% lower.
KNSA EPS growth
KNSA Price vs fair value
KNSA PEG vs peers
Relative to its peers, KNSA's PEG ratio is lower than OMER's yet above ORMP's.
Frequently asked questions
What is Kiniksa Pharmaceuticals's PEG ratio?
Based on Sep 23, 2026 data, KNSA has a PEG ratio of 0.04.
What is the 3-year average PEG ratio for Kiniksa Pharmaceuticals (KNSA)?
Across the past 3 years, KNSA's PEG ratio has averaged at 0.76.
What is the 5-year average PEG ratio for Kiniksa Pharmaceuticals (KNSA)?
Across the past 5 years, KNSA's PEG ratio has averaged at 0.43.
What is the highest PEG ratio for KNSA?
The Jun 2025 quarter marked the four years high at 3.29 for KNSA's PEG ratio.
How does the current PEG ratio for KNSA compare to its historical average?
At present, KNSA's PEG ratio is 91% lower than its 4-year historical average.
Why is Kiniksa Pharmaceuticals's PEG ratio so low?
Strong earnings growth relative to valuation results in KNSA's low PEG ratio of 0.04.
How is KNSA's PEG ratio calculated (Kiniksa Pharmaceuticals PEG ratio formula)?
The PEG ratio derives from taking PE and dividing by the rate at which earnings are growing (YoY TTM). As of Sep 23, 2026, Kiniksa Pharmaceuticals has a PE ratio of 71.1. Earnings grew at 1683.3% over the TTM period ending Jun 2026. Applying the formula, this gives a PEG ratio of 0.04. PEG RATIO(0.04) = PE RATIO(71.1) / EPS GROWTH(1683.3%)
All PEG ratio stats are based on quarterly TTM periods, unless otherwise specified.